收藏切换
Analysis of the current development status and key points of quality management in clinical trials of nuclear medicine in China
收藏切换
Pei-pei SHI, Wei YE, Li-xin HUA, Li-jun TANG, Yi CHAI*
Chinese Journal of New Drugs | 2026, 35(19) : 2090 - 2095
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(19): 2090-2095
Analysis of the current development status and key points of quality management in clinical trials of nuclear medicine in China
Full
Pei-pei SHI, Wei YE, Li-xin HUA, Li-jun TANG, Yi CHAI*
Affiliations
  • The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
Published: 2026-10-15 doi: 10.20251/j.cnki.1003-3734.2026.19.010
Outline
收藏切换

AbstractIn recent years, the global radiopharmaceutical industry has exhibited a marked trend of rapid growth, playing a pivotal role in the precise diagnosis and treatment of diseases such as oncology, cardiovascular disorders, and neurological conditons, and thus holding extensive application prospects. With the further advancement of precision medicine, clinical trials of radiopharmaceuticals have been increasingly conducted, providing critical evidence for the market approval of more innovative nuclear drugs. However, the quality management of radiopharmaceutical clinical trials present distinct priorities and challenges compared with that of general clinical trials. For example, the short half-life of radionuclides necessitates that investigational radiopharmaceuticals strict adherence to the time window for preparation, quality control, transportation, and administration-any delay at any step may compromise the reliability of trial outcomes. Additionally, radiopharmaceuticals involve unique considerations such as radiation safety, waste disposal, and accurate dose measurement, which impose higher requirements on personnel qualifications, storage and use management of nuclear drugs, radiation protection for participants and healthcare professionals, data traceability, and regulatory compliance. This paper reviews the development of nuclear drug clinical trials and the specific cases of radiopharmaceutical clinical trials conducted at our institution, and summarizes the key points and difficulties in quality control-covering personnel qualifications, nuclear drug management, safety protection, and data management-with the aim of providing useful references for the quality management of nuclear drug clinical trials at various clinical trial institutions.

radiopharmaceuticals  /  clinical trial  /  quality management
侍培培, 叶玮, 华立新, 唐立钧, 柴怡. 我国核药临床试验的发展现状及质量管理要点分析. 中国新药杂志, 2026 , 35 (19) : 2090 -2095 . DOI: 10.20251/j.cnki.1003-3734.2026.19.010
Pei-pei SHI, Wei YE, Li-xin HUA, Li-jun TANG, Yi CHAI. Analysis of the current development status and key points of quality management in clinical trials of nuclear medicine in China[J]. Chinese Journal of New Drugs, 2026 , 35 (19) : 2090 -2095 . DOI: 10.20251/j.cnki.1003-3734.2026.19.010
Year 2026 volume 35 Issue 19
65
13
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.19.010
  • Receive Date:2026-04-21
  • Online Date:2026-10-29
  • Published:2026-10-15
Article Data
Affiliations
History
  • Received:2026-04-21
Funding
Affiliations
    The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.19.010
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT